Monitor for shareholder approval filing which would enable full warrant exercise and trigger potential significant dilution. Watch for announcement of at-the-market program which would trigger the $8 million cash payment obligation.
Price Chart
Executive Summary
CDT Equity Inc. acquired a 20% stake in Sarborg Limited through a stock and warrant issuance valued at approximately $82.5 million, while also extending consulting agreements with two advisory firms for additional stock payments totaling $395,000. The deal includes a deferred $8 million cash payment contingent on future financing.
Key Financial Metrics
Key Facts
- CDT Equity acquired 20% of Sarborg Limited in exchange for 598,006 shares of common stock and pre-funded warrants to purchase 109,978,918 shares
- The transaction includes a deferred $8 million cash payment contingent on CDT raising at least $20 million through an at-the-market facility
- The pre-funded warrants have a nominal exercise price of $0.0001 per share but require shareholder approval for full exercise
- Two consulting agreements were extended with NJS Foresight Bio-Advisory ($150,000 in stock) and Thesprogen ($245,000 in stock)
- A director of CDT (Chele Farley) who is also a Sarborg shareholder participated in the transaction on the same terms as other investors
Financial Impact
Approximately $82.5 million in equity consideration (based on $0.75/share), plus $8 million deferred cash payment
Risk Factors
- Significant shareholder dilution upon warrant exercise (potentially over 90 million new shares)
- Contingent $8 million cash payment that depends on successful future financing
- Shareholder approval required for full warrant exercise, creating execution risk
- Concentration risk with pre-funded warrants held by former Sarborg shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-007906 |
| Exhibit: ex4-1.htm | 0001493152-26-007906 |
| Exhibit: ex10-3.htm | 0001493152-26-007906 |
| Exhibit: ex10-2.htm | 0001493152-26-007906 |
| Document: form8-k.htm | 0001493152-26-007906 |
| Document: 0001493152-26-007906-index-headers.html | 0001493152-26-007906 |
| Document: 0001493152-26-007906-index.html | 0001493152-26-007906 |
| Document: 0001493152-26-007906.txt | 0001493152-26-007906 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $37.00 $1.40 | ▲ +96.23% | ▲ +97.41% | $1.25 (+96.62%) |
Jul 31, 2026 9w ago | 8-K | $2.87 $1.68 | ▲ +41.36% | ▲ +42.60% | $1.25 (+56.37%) |
Jul 16, 2026 11w ago | 8-K | $0.3550 $3.15 | ▼ −785.92% | ▼ −782.30% | $1.25 (−252.11%) |
Jun 29, 2026 13w ago | 8-K | $0.5600 $2.85 | ▼ −408.04% | ▼ −409.06% | $1.25 (−123.21%) |
Jun 16, 2026 15w ago | 8-K | $0.6930 $0.3550 | ▲ +48.77% | ▲ +50.09% | $1.25 (−80.38%) |
May 6, 2026 21w ago | Press Release | $2.26 $0.8050 | ▼ −64.38% | ▼ −67.16% | $1.25 (−44.69%) |
Mar 4, 2026 30w ago | Press Release | $17.70 $5.10 | ▼ −71.19% | ▼ −66.77% | $1.25 (−92.94%) |
Feb 24, 2026 31w ago | 8-K | $17.25 $10.88 | ▼ −36.96% | ▼ −31.72% | $1.25 (−92.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access